AR080264A1 - Inhibidores ns5a de vhc - Google Patents

Inhibidores ns5a de vhc

Info

Publication number
AR080264A1
AR080264A1 ARP090104677A ARP090104677A AR080264A1 AR 080264 A1 AR080264 A1 AR 080264A1 AR P090104677 A ARP090104677 A AR P090104677A AR P090104677 A ARP090104677 A AR P090104677A AR 080264 A1 AR080264 A1 AR 080264A1
Authority
AR
Argentina
Prior art keywords
group
heteroaryl
independently
heterocycle
cycloalkyl
Prior art date
Application number
ARP090104677A
Other languages
English (en)
Inventor
Li Leping
Zhong Min
Original Assignee
Presidio Pharnaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42233598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR080264(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Presidio Pharnaceuticals Inc filed Critical Presidio Pharnaceuticals Inc
Publication of AR080264A1 publication Critical patent/AR080264A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Composiciones farmacéuticas y terapias de combinacion para la inhibicion del virus de la hepatitis C. Reivindicacion 1: Un compuesto que tiene la formula (1): donde: A y A' se seleccionan de manera independiente del grupo que consiste en un enlace simple, -(CR2)n-C(O)-(CR2)p-, -(CR2)n-O-(CR2)p-, -(CR2)n-N(RN)-(CR2)p-, -(CR2)n-S(O)k-N(RN)-(CR2)p-, -(CR2)n-C(O)-N (RN)-(CR2)p-, -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)p, -(CR2)n-C(O)-O-(CR2)p-, -(CR2)n-N(RN)-S(O)k-N(RN)-(CR2)p- y -(CR2)n-N(RN)-C(O)-O-(CR2)p, y un grupo heteroarilo seleccionado del grupo que consiste en (2) donde: X1 es CH2, NH, O o S; Y1, Y2 y Z1 son, de manera independiente, CH o N; X2 es NH, O o S; V es -CH2-CH2- , -CH=CH-, -N=CH- , (CH2)aN(RN)-(CH2)b- o -(CH2)a-O-(CH2)b-, donde a y b son, independientemente, 0; 1; 2; o 3, con la condicion de que a y b no son ambos 0; (3) opcionalmente incluye 1 o 2 nitrogenos como heteroátomos en el residuo fenilo; los carbonos del grupo heteroarilo, de manera independiente, están opcionalmente sustituidos con un sustituyente seleccionado del grupo que consiste en -OH, -CN, -NO2, halogeno, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxi, alcoxicarbonilo, alcanoílo, carbamoílo, sulfonilo sustituido, sulfonato, sulfonamida y amino; los nitrogenos del grupo heteroarilo, si se presentan, están opcionalmente sustituidos, de manera independiente, con un sustituyente seleccionado del grupo que consiste en -OH, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxi, alcoxicarbonilo, alcanoílo, carbamoílo, sulfonilo sustituido, sulfonato y sulfonamida; a y b son, independientemente, 1; 2 o 3; c y d son, independientemente, 1 o 2; n y p son, independientemente, 0; 1; 2 o 3; k es 0; 1 o 2; cada R se selecciona de manera independiente del grupo que consiste en hidrogeno, -OH, -CN, -NO2, halogeno, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxi, alcoxicarbonilo, alcanoílo, carbamoílo, sulfonilo sustituido, sulfonato, sulfonamida y amino; cada RN se selecciona independientemente del grupo que consiste en hidrogeno, -OH, alquilo C1-12, heteroalquilo C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxi, alcoxicarbonilo, alcanoílo, carbamoílo, sulfonilo sustituido, sulfonato y sulfonamida; y donde para cada A y A', B puede estar unido a cualquier lateral de A y A', de modo que, en el caso de que A o A' sea (4), el A-B-A' puede ser cualquiera de: (5), B se selecciona del grupo que consiste en un enlace simple, un enlace triple, (6) donde cada W se selecciona de manera independiente del grupo que consiste en un grupo cicloalquilo, un grupo cicloalquenilo, un grupo heterocíclico, grupo arilo o grupo heteroarilo; Rc, Rd, Re y Rf se seleccionan independientemente del grupo que consiste en: hidrogeno, alquilo C1-8, heteroalquilo C1-8, aralquilo, y un anillo de 4 a 8 miembros que puede ser cicloalquilo, heterociclo, heteroarilo o arilo, donde: cada heteroátomo, si está presente, es independientemente N, O o S; cada Rc, Rd, Re y Rf pueden estar opcionalmente sustituidos con alquilo C1-8, heteroalquilo C1-8, aralquilo, o un anillo de 4 a 8 miembros que puede ser cicloalquilo, heterociclo, heteroarilo o arilo, y donde cada heteroátomo, si está presente, es de manera independiente N, O o S; Rc y Rd están opcionalmente unidos para formar un heterociclo de 4 a 8 miembros, que, en forma opcional, está fusionado a otro anillo heteroarilo o heterociclo de 3 a 6 miembros; y Re y Rf están opcionalmente unidos para formar un heterociclo de 4 a 8 miembros, que, en forma opcional, esta fusionado a otro anillo heteroarilo o heterociclo de 3 a 6 miembros; Y e Y' son, independientemente, carbono o nitrogeno; y Z y Z' se seleccionan independientemente del grupo que consiste en hidrogeno, alquilo C1-8, heteroalquilo C1-8, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, 1-3 aminoácidos, -[U-(CR42)t-NR5-(CR42)t]u-U-(CR42)t-NR7-(CR42)t-R8, -U-(CR42)t-R8, y -[U-(CR42)t-NR5-(CR42)t]u-U-(CR42)t-O-(CR42)t-R8, donde: U se selecciona del grupo que consiste en -C(O)-, -C(S)- y -S(O)2-, cada R4, R5 y R7 se selecciona de modo independiente del grupo que consiste en hidrogeno, alquilo C1-8, heteroalquilo C1-8, cicloalquilo, heterociclo, arilo, heteroarilo y aralquilo; R8 se selecciona del grupo que consiste en hidrogeno, alquilo C1-8, heteroalquilo C1-8, cicloalquilo, heterociclo, arilo, heteroarilo y aralquilo, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-R812, -S(O)2-R81, -S(O)2-N-R812, donde cada R81 se selecciona de modo independiente del grupo que consiste en hidrogeno, alquilo C1-8, heteroalquilo C1-8, cicloalquilo, heterociclo, arilo, heteroarilo y aralquilo; opcionalmente, R7 y R8 juntos forman un anillo de 4 a 7 miembros; cada t es, independientemente, 0; 1; 2; o 4; y u es 0; 1 o 2.
ARP090104677A 2008-12-03 2009-12-03 Inhibidores ns5a de vhc AR080264A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11972308P 2008-12-03 2008-12-03
US17359009P 2009-04-28 2009-04-28
US18295209P 2009-06-01 2009-06-01
PCT/US2009/066451 WO2010065668A1 (en) 2008-12-03 2009-12-02 Inhibitors of hcv ns5a

Publications (1)

Publication Number Publication Date
AR080264A1 true AR080264A1 (es) 2012-03-28

Family

ID=42233598

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090104677A AR080264A1 (es) 2008-12-03 2009-12-03 Inhibidores ns5a de vhc
ARP090104678A AR074474A1 (es) 2008-12-03 2009-12-03 Inhibidores ns5a de vhc

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP090104678A AR074474A1 (es) 2008-12-03 2009-12-03 Inhibidores ns5a de vhc

Country Status (20)

Country Link
US (3) US9120779B2 (es)
EP (3) EP2774927A1 (es)
JP (2) JP2012510525A (es)
KR (1) KR20110098779A (es)
CN (2) CN102300462B (es)
AR (2) AR080264A1 (es)
AU (2) AU2009322387A1 (es)
BR (1) BRPI0922364A2 (es)
CA (2) CA2745119A1 (es)
CL (1) CL2011001332A1 (es)
CO (1) CO6390076A2 (es)
EA (1) EA201190007A1 (es)
IL (2) IL213278A0 (es)
MX (1) MX2011005896A (es)
NZ (2) NZ593808A (es)
PE (1) PE20120207A1 (es)
SG (2) SG171891A1 (es)
TW (2) TWI472526B (es)
WO (2) WO2010065668A1 (es)
ZA (1) ZA201104911B (es)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
PT2373172E (pt) * 2008-12-03 2013-10-21 Presidio Pharmaceuticals Inc Inibidores de ns5a de hcv
CA2740195A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
WO2010075376A2 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
TWI438200B (zh) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8420686B2 (en) 2009-02-17 2013-04-16 Enanta Pharmaceuticals, Inc. Linked diimidazole antivirals
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8637561B2 (en) 2009-02-17 2014-01-28 Enanta Pharmaceuticals, Inc. Linked diimidazole derivatives
US8426458B2 (en) 2009-02-27 2013-04-23 Enanta Pharmaceuticals, Inc. Hepatitis C Virus inhibitors
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) * 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
AU2013204195B2 (en) * 2009-02-27 2016-09-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2010099527A1 (en) * 2009-02-27 2010-09-02 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2010111673A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
US8796466B2 (en) * 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI476190B (zh) * 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2419404B1 (en) * 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
WO2010132538A1 (en) 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
NZ706236A (en) 2009-05-13 2016-07-29 Gilead Pharmasset Llc Antiviral compounds
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2010253791A1 (en) * 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
EP2435421A1 (en) * 2009-05-29 2012-04-04 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
DK2455376T3 (en) 2009-06-11 2015-03-02 Abbvie Bahamas Ltd Heterocyclic compounds as inhibitors of hepatitis C virus (HCV)
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011009084A2 (en) 2009-07-16 2011-01-20 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
CN102471327A (zh) 2009-07-21 2012-05-23 吉里德科学公司 黄病毒科病毒的抑制剂
US8623899B2 (en) 2009-08-07 2014-01-07 Janssen Research & Development Ireland Bis-benzimidazole derivatives as hepatitis C virus inhibitors
CA2768637A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Phenyl ethynyl derivatives as hepatitis c virus inhibitors
BR112012004969A2 (pt) 2009-09-03 2019-09-24 Tibotec Pharm Ltd derivados de bis-benzimidazol
WO2011028596A1 (en) 2009-09-04 2011-03-10 Glaxosmithkline Llc Chemical compounds
CA2771124C (en) 2009-09-09 2019-01-15 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031934A1 (en) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011031904A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) * 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) * 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011081918A1 (en) 2009-12-14 2011-07-07 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
CN104530079B (zh) * 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
US20130072523A1 (en) * 2009-12-24 2013-03-21 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP3219713A1 (en) 2010-01-15 2017-09-20 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
EP2523951B1 (en) 2010-01-15 2015-04-22 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
US8785487B2 (en) 2010-01-25 2014-07-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
CA2791630A1 (en) 2010-03-04 2011-09-09 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as inhibitors of hcv replication
AU2011224698A1 (en) 2010-03-09 2012-11-01 Merck Sharp & Dohme Corp. Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases
CA2794145A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
TW201141857A (en) * 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
MX2012012204A (es) 2010-04-22 2012-12-05 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
CA2800530A1 (en) * 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011156543A2 (en) * 2010-06-09 2011-12-15 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a protein
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
AR081691A1 (es) 2010-06-28 2012-10-10 Vertex Pharma Derivados de tiofeno, metodos para su preparacion y su uso en el tratamiento o la prevencion de infecciones por flavivirus
AU2011286276A1 (en) 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
PL2598498T3 (pl) 2010-07-26 2014-12-31 Janssen Sciences Ireland Uc Hetero-bicykliczne pochodne jako inhibitory HCV
CA2807305A1 (en) * 2010-08-04 2012-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2012021704A1 (en) 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2012024363A2 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
EP2963034A1 (en) * 2010-08-26 2016-01-06 RFS Pharma, LLC. Potent and selective inhibitors of hepatitis c virus
WO2012040389A2 (en) * 2010-09-22 2012-03-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
EP2619195A1 (en) * 2010-09-24 2013-07-31 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN103459399A (zh) * 2010-09-29 2013-12-18 默沙东公司 用于治疗丙型肝炎病毒感染的四环吲哚衍生物
US9254292B2 (en) 2010-09-29 2016-02-09 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
EP2621931A4 (en) * 2010-09-29 2014-03-19 Merck Sharp & Dohme TETRACYCLIC INDOLATE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION
AU2014203655B2 (en) * 2010-10-13 2016-07-07 Abbvie Ireland Unlimited Company Anti-viral compounds
MY164064A (en) * 2010-10-13 2017-11-15 Abbvie Bahamas Ltd Anti-viral compounds
MX2013004655A (es) 2010-10-26 2013-08-27 Presidio Pharmaceuticals Inc Inhibidores del virus de la hepatitis c.
CN103189371B (zh) 2010-11-04 2015-04-01 施万生物制药研发Ip有限责任公司 丙型肝炎病毒抑制剂
SG10201509456SA (en) 2010-11-17 2015-12-30 Gilead Pharmasset Llc Antiviral compounds
RU2452735C1 (ru) * 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
US20140364616A1 (en) * 2010-12-15 2014-12-11 Abbvie Inc. Anti-viral compounds
US20150031884A1 (en) * 2010-12-15 2015-01-29 Abbvie Inc. Anti-viral compounds
WO2012083058A2 (en) * 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
WO2012083048A2 (en) * 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
MX2013006951A (es) * 2010-12-16 2013-10-03 Abbvie Inc Compuestos antivirales.
WO2012087976A2 (en) * 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2012091115A1 (ja) * 2010-12-29 2012-07-05 キッセイ薬品工業株式会社 アセチレン誘導体及びその医薬用途
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP2709455A4 (en) 2011-05-18 2014-11-05 Enanta Pharm Inc PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES
CA2840445A1 (en) 2011-07-13 2013-01-17 Gilead Sciences, Inc. Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
TW201317223A (zh) 2011-07-26 2013-05-01 Vertex Pharma 噻吩化合物
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES
UA116087C2 (uk) 2011-09-16 2018-02-12 Гіліад Фармассет Елелсі Композиція для лікування вірусу гепатиту c
PL3431477T3 (pl) 2011-11-16 2021-04-06 Gilead Pharmasset Llc Skondensowane imidazoliloimidazole jako związki przeciwwirusowe
CN103987723B (zh) * 2011-12-16 2017-03-01 弗·哈夫曼-拉罗切有限公司 Hcv ns5a 的抑制剂
CA2858646A1 (en) 2011-12-28 2013-07-04 Janssen R&D Ireland Quinazolinone derivatives as hcv inhibitors
RU2621734C1 (ru) * 2011-12-28 2017-06-07 Янссен Сайенсиз Айрлэнд Юси Гетеробициклические производные в качестве ингибиторов hcv
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9073943B2 (en) * 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
CA2870264C (en) 2012-04-17 2016-11-08 Fujifilm Corporation Nitrogen-containing heterocyclic compound or salt thereof
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US9802949B2 (en) 2012-11-29 2017-10-31 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
CN103848821B (zh) 2012-11-29 2016-10-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途
CN103880823B (zh) * 2012-12-21 2017-12-05 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用
KR20140119012A (ko) 2013-01-31 2014-10-08 길리어드 파마셋 엘엘씨 두 항바이러스 화합물의 병용 제형물
RU2507201C1 (ru) 2013-02-07 2014-02-20 Александр Васильевич Иващенко Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
EP3063140A4 (en) 2013-10-30 2017-11-08 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
WO2015089810A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
CN103664581B (zh) * 2013-12-20 2016-07-06 中节能万润股份有限公司 一种反，反-4,4’-二环己基二甲酸的制备方法
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015110048A1 (en) 2014-01-23 2015-07-30 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
ES2957761T3 (es) 2014-04-15 2024-01-25 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
CN105175408B (zh) * 2014-06-04 2018-07-17 中国人民解放军第二军医大学 苯并噻唑类化合物及其作为药物的用途
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN106279117A (zh) * 2016-08-16 2017-01-04 上海同昌生物医药科技有限公司 一种雷迪帕韦中间体的合成方法及其产品
CN108727345B (zh) * 2017-04-25 2023-06-27 广东东阳光药业有限公司 一种咪唑环中间体的制备方法
US20220099637A1 (en) 2018-12-04 2022-03-31 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
CN115835907A (zh) 2020-05-22 2023-03-21 安力高医药股份有限公司 用于靶向pd-l1的方法和组合物
MX2023007793A (es) 2020-12-30 2023-09-22 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas.
JP2024519910A (ja) 2021-05-21 2024-05-21 ギリアード サイエンシーズ， インコーポレイテッド ジカウイルス阻害剤としての五環式誘導体
KR20240035395A (ko) 2021-06-14 2024-03-15 스코르피온 테라퓨틱스, 인코퍼레이티드 암 치료에 사용할 수 있는 요소 유도체

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1244507B (it) * 1991-04-11 1994-07-15 Sigma Tau Ind Farmaceuti Derivati dell'acido piroglutammico quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
DE4234295A1 (de) 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
JPH09227417A (ja) * 1996-02-26 1997-09-02 Dainippon Ink & Chem Inc アルケニルトラン誘導体とその製造方法
NZ332405A (en) 1996-04-23 2000-06-23 Vertex Pharma oxazolyl, thiazolyl or phenyl urea derivatives as inhibitors of inosine monophosphate dehydrogenase enzyme
JP3865084B2 (ja) * 1996-07-04 2007-01-10 大日本インキ化学工業株式会社 ジアルケニルトラン誘導体
EP2409985A3 (en) 1996-10-18 2013-05-01 Vertex Pharmaceuticals Incorporated Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
ES2201452T3 (es) 1997-03-14 2004-03-16 Vertex Pharmaceuticals Incorporated Inhibidores de la enzima impdh.
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
ES2234144T3 (es) 1997-08-11 2005-06-16 Boehringer Ingelheim (Canada) Ltd. Analogos de peptidos inhibidores de la hepatitis c.
DE69925918T2 (de) 1998-07-27 2006-05-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketosäure-derivate als hemmstoffe von polymerasen
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
BR9913157A (pt) 1998-08-21 2001-05-15 Viropharma Inc Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, composto
AU751201B2 (en) 1998-09-04 2002-08-08 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
JP2002525295A (ja) 1998-09-25 2002-08-13 バイロファーマ・インコーポレイテッド ウイルス感染および関連疾患の治療または予防法
TR200103428T2 (tr) 1999-03-19 2002-04-22 Vertex Pharmaceuticals Incorporated IMPDH enzim inhibitörleri.
WO2000066578A1 (en) * 1999-04-30 2000-11-09 Pfizer Products Inc. Compounds for the treatment of obesity
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
JP2001294541A (ja) * 2000-04-14 2001-10-23 Dainippon Ink & Chem Inc トラン誘導体の製造方法
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
JP4544857B2 (ja) 2001-06-11 2010-09-15 ヴァイロケム ファーマ インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の治療または予防のための化合物および方法
WO2002100846A1 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003007959A1 (en) * 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
EP1440069B1 (en) 2001-11-02 2007-08-15 Glaxo Group Limited 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
JP2005511572A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体
JP2005511573A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としての４−（５−員）−ヘテロアリールアシルピロリジン誘導体
JP2006505570A (ja) * 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
JP4206382B2 (ja) 2002-11-19 2009-01-07 アキリオン ファーマシューティカルズ，インコーポレーテッド 置換されたアリールチオウレアおよび関連化合物；ウイルス複製のインヒビター
AU2003294443A1 (en) * 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 3-(pyridinyl-piperazin-1-yl)-phenylethyl amides as potassium channel openers
JP4584909B2 (ja) 2003-05-09 2010-11-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスｎｓ５ｂポリメラーゼインヒビター結合ポケット
JP2007534624A (ja) * 2003-07-16 2007-11-29 ニューロジェン・コーポレーション ビアリールピペラジニル−ピリジン類縁体
WO2005073195A2 (en) 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
KR20070083484A (ko) 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. Ｃ형 간염 치료 방법
UA90477C2 (ru) 2004-07-14 2010-05-11 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способ лечения гепатита с (варианты)
US8143288B2 (en) * 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
BRPI0614242A2 (pt) * 2005-07-29 2011-03-15 Medivir Ab inibidores macrocìclicos do vìrus da hepatite c, combinação e composição farmacêutica compreendendo os mesmos, bem como uso e processo para a preparação dos referidos inibidores
TW200813015A (en) 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20090086081A (ko) 2006-11-15 2009-08-10 바이로켐 파마 인코포레이티드 플라비바이러스 감염의 치료 또는 예방용 티오펜 유사체
WO2008073461A2 (en) * 2006-12-11 2008-06-19 Wyeth Ion channel modulators
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
CN101280196B (zh) * 2008-06-03 2011-01-26 西安近代化学研究所 四环液晶化合物
US7906655B2 (en) * 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PT2373172E (pt) * 2008-12-03 2013-10-21 Presidio Pharmaceuticals Inc Inibidores de ns5a de hcv
EP2393359A4 (en) 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
WO2010099527A1 (en) * 2009-02-27 2010-09-02 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
NZ706236A (en) * 2009-05-13 2016-07-29 Gilead Pharmasset Llc Antiviral compounds

Also Published As

Publication number Publication date
IL213278A0 (en) 2011-07-31
US20150038501A1 (en) 2015-02-05
AU2009322387A1 (en) 2011-06-30
EP2373167A4 (en) 2012-07-25
JP2012510523A (ja) 2012-05-10
US9120779B2 (en) 2015-09-01
WO2010065681A1 (en) 2010-06-10
IL213279A0 (en) 2011-07-31
US20110237579A1 (en) 2011-09-29
CA2750577A1 (en) 2010-06-10
TWI494309B (zh) 2015-08-01
WO2010065668A1 (en) 2010-06-10
AR074474A1 (es) 2011-01-19
CL2011001332A1 (es) 2011-11-11
AU2009322400A1 (en) 2011-06-30
CN102300462A (zh) 2011-12-28
CN102300462B (zh) 2015-01-28
CN102300461B (zh) 2015-04-22
EP2373168A4 (en) 2012-08-01
TW201033196A (en) 2010-09-16
ZA201104911B (en) 2012-03-28
CA2745119A1 (en) 2010-06-10
BRPI0922364A2 (pt) 2017-08-29
PE20120207A1 (es) 2012-03-31
EP2774927A1 (en) 2014-09-10
NZ593808A (en) 2014-04-30
TW201031654A (en) 2010-09-01
KR20110098779A (ko) 2011-09-01
CN102300461A (zh) 2011-12-28
SG171890A1 (en) 2011-07-28
US8865756B2 (en) 2014-10-21
EA201190007A1 (ru) 2012-06-29
EP2373167A1 (en) 2011-10-12
JP2012510525A (ja) 2012-05-10
SG171891A1 (en) 2011-07-28
NZ593806A (en) 2014-04-30
EP2373168A1 (en) 2011-10-12
TWI472526B (zh) 2015-02-11
MX2011005896A (es) 2011-09-29
CO6390076A2 (es) 2012-02-29
US20120115855A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
AR080264A1 (es) Inhibidores ns5a de vhc
AR081831A1 (es) Inhibidores de la proteina ns5a del virus de la hepatitis c (vhc)
AR080263A1 (es) Inhibidores ns5a de vhc
AR084388A1 (es) Compuestos nitrogenados heterociclicos inhibidores de la replicacion del vhc y composiciones farmaceuticas que los contienen
AR076164A1 (es) Inhibidores de anillos fusionados de hepatitis c
AR081848A1 (es) Inhibidores de la proteina ns5a del vhc
AR084720A1 (es) Inhibidores de anillos fusionados triciclicos de hepatitis c
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
AR044519A1 (es) Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
AR058700A1 (es) Compuestos heterociclicos como bloqueadores del canal de sodio epitelial
AR054088A1 (es) Triazoles como inhibidores de proteinquinasas. composiciones farmaceuticas
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
CO6251243A2 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
AR081994A1 (es) Derivados de [1,8]naftiridina, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento de enfermedades inducidas por quinasas, en particular diferentes tipos de canceres
CO5601021A2 (es) Derivados de quinazolinona, composiciones farmaceuticas que los contienen y su proceso de preparacion y su uso como antagonistas cb
AR036492A1 (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
AR076810A1 (es) Compuestos anticancerigenos de amino pirimidina
AR074670A1 (es) Inhibidores de la proteasa ns3 del vhc virus de la hepatitis c
AR023703A1 (es) N-carboniloximetilesteres de nitroetilendiaminas y nitroguanidinas, proceso para su preparacion, composicion parasiticida, una preparacion en combinacionpara controlar parasitos en animales de sangre caliente, uso de dichos compuestos y compuestos intermediarios para su uso en dicho proceso de prepa
CO6260074A2 (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
AR061642A1 (es) Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas
AR054369A1 (es) Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa
AR049443A1 (es) Derivados de pirrolpiridinas
AR052660A1 (es) Derivados de pirazol para inhibir la cdk's y gsk's
AR049170A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal

Legal Events

Date Code Title Description
FB Suspension of granting procedure